1. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017; 390:946.

2. Patton ME, Moline HL, Whitaker M, et al. Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025. MMWR Morb Mortal Wkly Rep 2025; 74:273.

3. Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:920.

4. Muller WJ, Madhi SA, Seoane Nuñez B, et al. Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. N Engl J Med 2023; 388:1533.

5. Walsh G, Walsh E. Biopharmaceutical benchmarks 2022. Nat Biotechnol 2022; 40:1722.

6. Simpson S, Burls A. A systematic review of the effectiveness and cost-effectiveness of palivizumab (Synagis) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection. 2001 

Submit a topic request: https://forms.monday.com/forms/659b439e15af3c32cd423e42df124213?r=use1

Visit our website: https://www.onecommunityhealth.org/

Follow us on Instagram: https://www.instagram.com/onecommunitygorge/